Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).…
Sun, 08 Jun 2025 17:01:00 GMT Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors ... please visit www.CancerVax.com. This press release may contain ...
Sat, 03 May 2025 02:00:00 GMT Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.
Wed, 26 May 2021 01:34:00 GMT The Company has entered into an agreement with UCLA to develop an immunotherapy breakthrough targeted at treating Ewing sarcoma, a rare but deadly soft tissue and bone cancer that primarily affects ...
Tue, 19 May 2020 17:00:00 GMT PHILADELPHIA -- "Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal ...
Sun, 20 Aug 2017 17:00:00 GMT There may no silver bullet for treating liver cancer or ... the liver-specific gene targets. The results were published in Molecular Systems Biology, an EMBO Press Journal. The researchers mapped ...
